NeoGenomics, Inc. (NEO) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers.
Analysis Summary
NeoGenomics, Inc. reported revenue of $727.3M in the most recent fiscal year, growing at a 5-year CAGR of 10.4%.
Trailing-twelve-month margins: gross margin 42.9%, operating margin -8.6%, net margin -6.8%.
At the current price of $18.94, NEO has negative trailing earnings (P/E not meaningful) and an ROE of -6.31%. Market capitalisation stands at $487M.
Balance sheet quality for NEO: current ratio of 4.3, net debt of $312.7M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $18.94 |
| Market Cap | $487M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.62 |
| EV / EBITDA | 58.16 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -5.03% |
| Return on Assets | -3.84% |
| Gross Margin | 42.92% |
| Operating Margin | -8.63% |
| Net Margin | -6.77% |
Financial Health
| Debt / Equity | 0.57 |
| Current Ratio | 3.60 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 0.53 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NEO | NeoGenomics, Inc. | $487M | 0.62 | -6.3% | |
| TMO | Thermo Fisher Scientific Inc. | $241.0B | 36.16 | 4.74 | 13.4% |
| 0R0H.L | Thermo Fisher Scientific Inc. | $225.7B | 32.73 | 4.11 | 12.6% |
| 0R2B.L | Danaher Corporation | $142.2B | |||
| DHR | Danaher Corporation | $140.6B | 37.04 | 2.81 | 7.7% |
| 0HAV.L | Agilent Technologies, Inc. | $49.3B | 30.43 | 5.93 | 20.5% |
| NTRA | Natera, Inc. | $46.7B | 27.16 | -12.2% | |
| IQV | IQVIA Holdings Inc. | $44.2B | 34.40 | 7.58 | 20.9% |
Price Performance
| 1 month | +19.12% |
| 3 months | +70.17% |
| Year-to-date | +61.05% |
| 1 year | +133.54% |
| 3 years | +44.80% |
52-Week Range
| 52-week High | $19.76 |
| 52-week Low | $7.07 |
| Avg Volume (90d) | 2.4M |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2020-12-17 | $0.4000 | 8.45% |
Related companies: ACRS · ARCT · HUMA · MDXH · QTRX · SGMT · SMTI
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NEO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks